Sixty patients with port wine stains were treated with the argon laser and graded visually into four subjective categories for changes in skin colour. For objective quantitative evaluation a photoelectric colorimeter was used. Reproducible definition of the lightness of the lesions into numbers was obtained. Differentials in lightness between normal contralateral skin and the port wine stain before and after treatment were quantified for each individual. The objective evaluation revealed a statistically significant difference between the four categories (P less than 0.05). The best clinical therapeutic effect was found to correlate with only 80-90% blanching. The average lightening obtained was 46.5%. Local heating of port wine stains in 12 patients showed no measurable darkening in the colour of the lesions, whereas the normal contralateral skin reacted with marked reddening. Determination of changes in lightness by photoelectric colorimetry provides an objective, quantitative means to evaluate the effects of laser treatment of port wine stains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2133.1991.tb00430.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of hemoporfin photodynamic therapy in treating port-wine stains in Chinese children: a systematic review and meta-analysis.
Front Pediatr
January 2025
Department of Dermatology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing, China.
Objective: The purpose of this study is to explore the efficacy and safety of hematoporphyrin monomethyl ether mediated photodynamic therapy (HMME-PDT) in treating children with port-wine stains (PWS).
Method: Literature related to the topic was searched in PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, and China Science Technology Journal Database online databases. The quality of the literature was evaluated using the Effective Public Health Practice Project.
Development of optical microneedle-lens array for photodynamic therapy.
Biomed Microdevices
January 2025
Institute of Industrial Science, The University of Tokyo, Meguro-Ku, 153-8505, Tokyo, Japan.
Recently, photodynamic therapy (PDT) which involves a photosensitizer (PS), a special drug activated by light, and light irradiation has been widely used in treating various skin diseases such as port-wine stain as well as cancers such as melanoma and non-melanoma skin cancers. PDT comprises two general steps: the introduction of PS into the body or a specific spot to be treated, and the irradiation process using a light source with a specific wavelength to excite the PS. Although PDT is gaining great attention owing to its potential as a targeted approach in the treatment of skin cancers, several limitations still exist for practical use.
View Article and Find Full Text PDFPhakomatosis pigmentovascularis type 2a: a rare case report.
AME Case Rep
December 2024
Department of Dermatology, King Fahad Medical City, Riyadh, Saudi Arabia.
Background: Phakomatosis pigmentovascularis (PPV) is a rare congenital cutaneous syndrome characterized by capillary malformation and extensive dermal melanosis. The complexity of PPV is reflected in its evolving classification systems. Systemic manifestations encompass ocular, neurological, vascular, musculoskeletal, and renal involvement.
View Article and Find Full Text PDFA phase II double-blind multicentre, placebo-controlled trial to assess the efficacy and safety of alpelisib (BYL719) in paediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP): the SESAM study protocol.
BMJ Open
December 2024
INSERM UMR1231 Génétique des Anomalies du Développement (GAD), Université de Bourgogne, Dijon, France.
Introduction: The megalencephaly capillary malformation polymicrogyria (MCAP syndrome) results from mosaic gain-of-function variants. The main clinical features are macrocephaly, somatic overgrowth, neurodevelopmental delay and brain anomalies. Alpelisib (Vijoice) is a recently FDA-approved PI3Kα-specific inhibitor for patients with PIK3CA-related overgrowth spectrum (PROS).
View Article and Find Full Text PDFLasers for Medical Indications: Port-Wine Birthmarks and Beyond.
J Am Acad Dermatol
December 2024
Departments of Dermatology, Otolaryngology, Surgery, and Medical Social Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, USA. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!